Top

Journal of Cardiovascular Translational Research

Published in:

01-12-2019 | Original Article

Ligustrazine Protects Homocysteine-Induced Apoptosis in Human Umbilical Vein Endothelial Cells by Modulating Mitochondrial Dysfunction

Authors: Xuesong Fan, Enshi Wang, Jianxun He, Lei Zhang, Xiaoli Zeng, Yuan Gui, Qi Sun, Yang Song, Hui Yuan

Published in: Journal of Cardiovascular Translational Research | Issue 6/2019

Abstract

Ligustrazine is one of the alkaloid compounds isolated from the traditional Chinese herb, which shows protective effects on cardiovascular disorders. High homocysteine (Hcy) level can predict cardiovascular-related events including death. In this study, we used Hcy to stimulate the human umbilical vein endothelial cells (HUVECs) and investigated the protective effect of ligustrazine on endothelial dysfunction by assessing the cell apoptosis, oxidative damage, mitochondrial dysfunction, and the potential molecular pathways. Our results clearly showed that ligustrazine increased HUVEC cell viability, decreased the dehydrogenase (LDH) level, and inhibited HUVEC apoptosis, which was associated with the attenuation of attenuated oxidative damage. The mitochondrial-dependent pathway was closely related in the regulation of ligustrazine, reflected by the attenuated mitochondrial membrane potential change and decreased cytochrome c release from the mitochondria to the cytosol. Ligustrazine may protect Hcy-induced apoptosis in HUVECs by attenuating oxidative damage and modulating mitochondrial dysfunction.

Available only for authorised users

Clarke, R., Daly, L., Robinson, K., Naughten, E., Cahalane, S., Fowler, B., et al. (1991). Hyperhomocysteinemia: an independent risk factor for vascular disease. The New England Journal of Medicine, 324(17), 1149–1155. https://doi.org/10.1056/nejm199104253241701.CrossRefPubMed

Marasini, B., Massarotti, M., & Biondi, M. L. (2002). Homocysteine and vascular diseases. Circulation, 106(7), e33.CrossRefPubMed

Nygard, O., Nordrehaug, J. E., Refsum, H., Ueland, P. M., Farstad, M., & Vollset, S. E. (1997). Plasma homocysteine levels and mortality in patients with coronary artery disease. The New England Journal of Medicine, 337(4), 230–236. https://doi.org/10.1056/nejm199707243370403.CrossRefPubMed

Wu, X., Zhang, L., Miao, Y., Yang, J., Wang, X., Wang, C. C., et al. (2018). Homocysteine causes vascular endothelial dysfunction by disrupting endoplasmic reticulum redox homeostasis. Redox Biology, 20, 46–59. https://doi.org/10.1016/j.redox.2018.09.021.CrossRefPubMedPubMedCentral

Shi, W., Wang, X., Shih, D. M., Laubach, V. E., Navab, M., & Lusis, A. J. (2002). Paradoxical reduction of fatty streak formation in mice lacking endothelial nitric oxide synthase. Circulation, 105(17), 2078–2082.CrossRefPubMed

Liu, C., & Huang, Y. (2016). Chinese herbal medicine on cardiovascular diseases and the mechanisms of action. Frontiers in Pharmacology, 7, 469. https://doi.org/10.3389/fphar.2016.00469.CrossRefPubMedPubMedCentral

Chang, Y., Hsiao, G., Chen, S. H., Chen, Y. C., Lin, J. H., Lin, K. H., et al. (2007). Tetramethylpyrazine suppresses HIF-1alpha, TNF-alpha, and activated caspase-3 expression in middle cerebral artery occlusion-induced brain ischemia in rats. Acta Pharmacologica Sinica, 28(3), 327–333. https://doi.org/10.1111/j.1745-7254.2007.00514.x.CrossRefPubMed

Fan, L. H., Wang, K. Z., Cheng, B., Wang, C. S., & Dang, X. Q. (2006). Anti-apoptotic and neuroprotective effects of tetramethylpyrazine following spinal cord ischemia in rabbits. BMC Neuroscience, 7, 48. https://doi.org/10.1186/1471-2202-7-48.CrossRefPubMedPubMedCentral

Wu, H. J., Hao, J., Wang, S. Q., Jin, B. L., & Chen, X. B. (2012). Protective effects of ligustrazine on TNF-alpha-induced endothelial dysfunction. European Journal of Pharmacology, 674(2–3), 365–369. https://doi.org/10.1016/j.ejphar.2011.10.046.CrossRefPubMed

10.

Yang, C., Xu, Y., Zhou, H., Yang, L., Yu, S., Gao, Y., et al. (2016). Tetramethylpyrazine protects CoCl2-induced apoptosis in human umbilical vein endothelial cells by regulating the PHD2/HIF/1alpha-VEGF pathway. Molecular Medicine Reports, 13(2), 1287–1296. https://doi.org/10.3892/mmr.2015.4679.CrossRefPubMed

11.

Tveden-Nyborg, P., Bergmann, T. K., & Lykkesfeldt, J. (2018). Basic & clinical pharmacology & toxicology policy for experimental and clinical studies. Basic & Clinical Pharmacology & Toxicology, 123(3), 233–235. https://doi.org/10.1111/bcpt.13059.CrossRef

12.

Deshmukh, M., & Johnson, E. M., Jr. (1998). Evidence of a novel event during neuronal death: development of competence-to-die in response to cytoplasmic cytochrome c. Neuron, 21(4), 695–705.CrossRefPubMed

13.

Rajendran, P., Rengarajan, T., Thangavel, J., Nishigaki, Y., Sakthisekaran, D., Sethi, G., et al. (2013). The vascular endothelium and human diseases. International Journal of Biological Sciences, 9(10), 1057–1069. https://doi.org/10.7150/ijbs.7502.CrossRefPubMedPubMedCentral

14.

Ansar, S., Koska, J., & Reaven, P. D. (2011). Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovascular Diabetology, 10, 61. https://doi.org/10.1186/1475-2840-10-61.CrossRefPubMedPubMedCentral

15.

Feletou, M., & Vanhoutte, P. M. (2006). Endothelium-derived hyperpolarizing factor: where are we now? Arteriosclerosis, Thrombosis, and Vascular Biology, 26(6), 1215–1225. https://doi.org/10.1161/01.ATV.0000217611.81085.c5.CrossRefPubMed

16.

Suwaidi, J. A., Hamasaki, S., Higano, S. T., Nishimura, R. A., Holmes, D. R., Jr., & Lerman, A. (2000). Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation, 101(9), 948–954.CrossRefPubMed

17.

Ross, R. (1999). Atherosclerosis--an inflammatory disease. The New England Journal of Medicine, 340(2), 115–126. https://doi.org/10.1056/nejm199901143400207.CrossRefPubMed

18.

Hofmann, M. A., Lalla, E., Lu, Y., Gleason, M. R., Wolf, B. M., Tanji, N., et al. (2001). Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. The Journal of Clinical Investigation, 107(6), 675–683. https://doi.org/10.1172/jci10588.CrossRefPubMedPubMedCentral

19.

Zhang, Z., Wei, C., Zhou, Y., Yan, T., Wang, Z., Li, W., et al. (2017). Homocysteine induces apoptosis of human umbilical vein endothelial cells via mitochondrial dysfunction and endoplasmic reticulum stress. Oxidative Medicine and Cellular Longevity, 2017, 5736506. https://doi.org/10.1155/2017/5736506.CrossRefPubMedPubMedCentral

20.

Peng, W., Hucks, D., Priest, R. M., Kan, Y. M., & Ward, J. P. (1996). Ligustrazine-induced endothelium-dependent relaxation in pulmonary arteries via an NO-mediated and exogenous L-arginine-dependent mechanism. British Journal of Pharmacology, 119(5), 1063–1071. https://doi.org/10.1111/j.1476-5381.1996.tb15778.x.CrossRefPubMedPubMedCentral

21.

Zhao, T., Fu, Y., Sun, H., & Liu, X. (2018). Ligustrazine suppresses neuron apoptosis via the Bax/Bcl-2 and caspase-3 pathway in PC12 cells and in rats with vascular dementia. IUBMB Life, 70(1), 60–70. https://doi.org/10.1002/iub.1704.CrossRefPubMed

22.

Chen, J., Chen, J., Wang, X., Wang, C., Cao, W., Zhao, Y., et al. (2016). Ligustrazine alleviates acute pancreatitis by accelerating acinar cell apoptosis at early phase via the suppression of p38 and Erk MAPK pathways. Biomedicine & Pharmacotherapy, 82, 1–7. https://doi.org/10.1016/j.biopha.2016.04.048.CrossRef

23.

Pan, J., Shang, J. F., Jiang, G. Q., & Yang, Z. X. (2015). Ligustrazine induces apoptosis of breast cancer cells in vitro and in vivo. Journal of Cancer Research and Therapeutics, 11(2), 454–458. https://doi.org/10.4103/0973-1482.147378.CrossRefPubMed

24.

Yip, K. W., & Reed, J. C. (2008). Bcl-2 family proteins and cancer. Oncogene, 27(50), 6398–6406. https://doi.org/10.1038/onc.2008.307.CrossRefPubMed

25.

Xu, Z., Lu, G., & Wu, F. (2009). Simvastatin suppresses homocysteine-induced apoptosis in endothelial cells: roles of caspase-3, cIAP-1 and cIAP-2. Hypertension Research, 32(5), 375–380. https://doi.org/10.1038/hr.2009.24.CrossRefPubMed

26.

Tait, S. W., & Green, D. R. (2010). Mitochondria and cell death: outer membrane permeabilization and beyond. Nature Reviews. Molecular Cell Biology, 11(9), 621–632. https://doi.org/10.1038/nrm2952.CrossRefPubMed

27.

Boatright, K. M., & Salvesen, G. S. (2003). Mechanisms of caspase activation. Current Opinion in Cell Biology, 15(6), 725–731.CrossRefPubMed

28.

Saleh, F. A., Whyte, M., & Genever, P. G. (2011). Effects of endothelial cells on human mesenchymal stem cell activity in a three-dimensional in vitro model. European Cells & Materials, 22, 242–257 discussion 257.CrossRef

Title: Ligustrazine Protects Homocysteine-Induced Apoptosis in Human Umbilical Vein Endothelial Cells by Modulating Mitochondrial Dysfunction
Authors: Xuesong Fan
Enshi Wang
Jianxun He
Lei Zhang
Xiaoli Zeng
Yuan Gui
Qi Sun
Yang Song
Hui Yuan
Publication date: 01-12-2019
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 6/2019
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-019-09900-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Ligustrazine Protects Homocysteine-Induced Apoptosis in Human Umbilical Vein Endothelial Cells by Modulating Mitochondrial Dysfunction

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2019

In Vitro and Ex Vivo Hemodynamic Testing of an Innovative Occluder for Paravalvular Leak After Transcather Aortic Valve Implantation

Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation

Application of Proteomics Profiling for Biomarker Discovery in Hypertrophic Cardiomyopathy

Prevalence of Cardiac Amyloidosis in Patients with Carpal Tunnel Syndrome

Exercise Attenuates Acute β-Adrenergic Overactivation–Induced Cardiac Fibrosis by Modulating Cytokines

3D Myocardial Scar Prediction Model Derived from Multimodality Analysis of Electromechanical Mapping and Magnetic Resonance Imaging

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page